Abstract

treated). HT-29. Continuous moderate to strong membrane staining is present in untreated and cetuximab or gefitinib treated cells. Strong granular cytoplasmic immunostaining was present for all treatments plus EGF, without any observable membrane staining. Caco-2. Continuous weak to moderate membrane brown staining is present in untreated as well as in cetuximab 5 nmol/L and gefitinib 1 μmol/L treated cells. Weak membrane immunostaining was present in cetuximab 10 nmol/L treated cells. The cytoplasmic immunostaining pattern was granular in EGF 10 nM, diffuse in gefitinib 1 μmol/L plus EGF 10 nM and a mixture of the two (granular and diffuse) in cetuximab 5 and 10 nmol/L plus EGF 10 nM treated cells.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

    Similar works

    Full text

    thumbnail-image

    Available Versions